Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review of mechanisms, clinical effects, and monitoring strategies without quantitative data or systematic synthesis methodology reported in the abstract
PubMed 32517786 · doi:10.1186/s42358-020-00134-8
What was done
The authors reviewed the immunomodulatory and anti-inflammatory mechanisms of hydroxychloroquine and chloroquine, their clinical effects on disease activity and survival in systemic lupus erythematosus, secondary effects (antiplatelet, metabolic, lipid benefits), potential adverse effects, and practical monitoring approaches for patients with chronic immune-mediated inflammatory rheumatic diseases.
What was found
The abstract provides a descriptive overview without presenting quantitative findings, effect sizes, statistical comparisons, or specific numerical data.
Why it matters
The paper contextualizes the established clinical utility and safety considerations of hydroxychloroquine and chloroquine in rheumatology, which gained broader attention during the COVID-19 pandemic.
Limits
The abstract describes a broad narrative overview without reporting a systematic search protocol, inclusion/exclusion criteria, study counts, patient numbers, or quantitative outcome measures.
Cited by
- supports Chloroquine and hydroxychloroquine are antimalarial agents that are used to treat rheumatoid arthritis due to their anti-inflammatory properties.